Extending the safe apnea window: preclinical evaluation of the Turbo® O₂ cap for hypoxia mitigation during difficult intubation

The Turbo® O₂ Cap is a novel, FDA Class I airway device designed to mitigate hypoxia during difficult intubation by delivering high-flow oxygen directly to the glottic area. This study evaluates the performance of the device in a porcine model simulating rapid sequence intubation (RSI) under conditions of paralysis and apnea. Three Yorkshire pigs underwent a total of 12 intubation cycles: six control cycles using a standard endotracheal tube (ETT) without oxygen, and six test cycles with the Turbo® O₂ Cap delivering 15 L/min of oxygen through the ETT. In all control cycles, oxygen saturation dropped from the mid-to-high 90s to below 75% in less than one minute. In contrast, all test cycles maintained oxygen saturation in the high 90s throughout the full 10-minute observation period. This difference was statistically significant (6/6 vs. 0/6 cycles, Fisher’s exact p = 0.002). No other current device or method has demonstrated this level of performance in preventing hypoxia during apneic intubation. The likely mechanism of action is passive diffusion: oxygen is delivered just proximal to the vocal cords, creating a steep concentration gradient that facilitates diffusion into the lungs despite the absence of active ventilation. The Turbo® O₂ Cap may represent the first practical, passive solution for hypoxia mitigation during RSI. While further studies in humans are needed, these results provide strong early evidence that the device can extend the safe apnea window and may improve outcomes during high-risk airway management.